• 1
    Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793800.
  • 2
    Anthony MN, Gardner L, Marks G et al. Factors associated with use of HIV primary care among persons recently diagnosed with HIV: examination of variables from the behavioural model of health-care utilization. AIDS Care 2007; 19: 195202.
  • 3
    Hocking JS, Rodger AJ, Rhodes DG, Crofts N. Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis – characteristics of individuals. Int J STD AIDS 2000; 11: 503508.
  • 4
    Abaynew Y, Deribew A, Deribe K. Factors associated with late presentation to HIV/AIDS care in South Wollo ZoneEthiopia: a case-control study. AIDS Res Ther 2011; 8: 8.
  • 5
    Althoff KN, Gange SJ, Klein MB et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010; 50: 15121520.
  • 6
    Bonjour MA, Montagne M, Zambrano M et al. Determinants of late disease-stage presentation at diagnosis of HIV infection in Venezuela: a case-case comparison. AIDS Res Ther 2008; 5: 6.
  • 7
    Kigozi IM, Dobkin LM, Martin JN et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2009; 52: 280289.
  • 8
    Mojumdar K, Vajpayee M, Chauhan NK, Mendiratta S. Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. BMC Public Health 2010; 10: 416.
  • 9
    Antinori A, Coenen T, Costagiola D et al. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12: 6164.
  • 10
    Janssen RS, Holtgrave DR, Valdiserri RO, Shepherd M, Gayle HD, De Cock KM. The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. Am J Public Health 2001; 91: 10191024.
  • 11
    Micek MA, Gimbel-Sherr K, Baptista AJ et al. Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr 2009; 52: 397405.
  • 12
    Johnson MO, Rose CD, Dilworth SE, Neilands TB. Advances in the conceptualization and measurement of Health Care Empowerment: development and validation of the Health Care Empowerment inventory. PLoS One [Research Support, N.I.H., Extramural]. 2012; 7: e45692.
  • 13
    Gallant JE, Adimora AA, Carmichael JK et al. Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition. Clin Infect Dis [Practice Guideline Research Support, Non-U.S. Gov't]. 2011 53: 10431050.
  • 14
    Mugavero MJ, Amico KR, Westfall AO et al. Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr [Research Support, N.I.H., Extramural]. 2012 59: 8693.
  • 15
    McNairy ML, El-Sadr WM. The HIV care continuum: no partial credit given. AIDS 2012; 10: 17351738.
  • 16
    Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010; 15: 38.
  • 17
    Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda 2011.
  • 18
    British HIV Association. Guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy. HIV Med 2012; 13: 185.
  • 19
    Mugavero MJ, Napravnik S, Cole SR et al. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis 2011; 53: 927935.
  • 20
    Reekie J, Gatell JM, Yust I et al. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS 2011; 25: 22592268.
  • 21
    Marras D, Bruggeman LA, Gao F et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002; 8: 522526.
  • 22
    Estrella M, Fine DM, Gallant JE et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 2006; 43: 377380.
  • 23
    Atta MG, Gallant JE, Rahman MH et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21: 28092813.
  • 24
    Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, PE K. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16: 24122420.
  • 25
    Kalayjian RC, Franceschini N, Gupta SK et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22: 481487.
  • 26
    Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493505.
  • 27
    Le T, Wright EJ, Smith DM. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368: 218230.
  • 28
    The SPARTAC Trial Investigators. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013; 368: 207217.
  • 29
    Stover K. NIH study examines best time for healthy HIV-infected people to begin antiretrovirals. Bethesda: National Institute of Allergy and Infectious Diseases 2011. [cited 2013 April 4].
  • 30
    Ferguson L, Lewis J, Grant AD et al. Patient attrition between diagnosis with HIV in pregnancy-related services and long-term HIV care and treatment services in Kenya: a retrospective study. J Acquir Immune Defic Syndr 2012; 60: 9097.
  • 31
    Ministerio da Saude, Secretaria de Vigilancia em Saude, Departamento de DST Aids e Hepatites Virais. Recomendacoes para profilaxia da transmissao vertical do HIV e terapia antirretroviral em gestantes. Brasilia 2010.
  • 32
    Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996–2004. PLoS One 2009; 4: e4445.
  • 33
    Sobrino-Vegas P, Garcia-San Miguel L, Caro-Murillo AM et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224230.
  • 34
    Yang B, Chan SK, Mohammad N et al. Late HIV diagnosis in Houston/Harris County, Texas, 2000–2007. AIDS Care 2010; 22: 766774.
  • 35
    Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004). AIDS 2006; 20: 23712379.
  • 36
    Delpierre C, Cuzin L, Lauwers-Cances V, Marchou B, Lang T. High-Risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population. AIDS Patient Care STDS 2006; 20: 838847.
  • 37
    Delpierre C, Cuzin L, Lert F. Routine testing to reduce late HIV diagnosis in France. BMJ 2007; 334: 13541356.
  • 38
    Hacker MA, Leite IC, Renton A, Torres TG, Graceie R, Bastos FI. Reconstructing the AIDS epidemic among injecting drug ssers. Cad Saude Publica 2006; 22: 751760.
  • 39
    Nhac-Vu HT, Giard M, Phong ND, Vanhems P. Risk factors for delayed HIV diagnosis at the Hospital of Tropical Diseases in Ho Chi Minh City, Vietnam. Int J STD AIDS 2010; 21: 802805.